Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.

Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jul 2013Cited by 164 (Europe PMC)

PMID23427056DOI10.1002/jbmr.1898PepBankPUB-23427056

Publisher page PubMedAsk about this study

Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 slowed body weight gain.
In plain wordsIn rats with ovaries removed, exendin‑4 slowed weight gain.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight gain
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Sixteen weeks of treatment with exendin-4 slowed down body weight gain by decreasing fat mass and prevented the loss of bone mass in old OVX rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705601
02AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 decreased fat mass.
In plain wordsIn rats with ovaries removed, exendin‑4 decreased fat mass.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFat mass
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Sixteen weeks of treatment with exendin-4 slowed down body weight gain by decreasing fat mass and prevented the loss of bone mass in old OVX rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705602
03AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 prevented bone mass loss.
In plain wordsIn rats with ovaries removed, exendin‑4 prevented bone mass loss.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBone mass loss
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Sixteen weeks of treatment with exendin-4 slowed down body weight gain by decreasing fat mass and prevented the loss of bone mass in old OVX rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705603
04AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 enhanced bone strength.
In plain wordsIn rats with ovaries removed, exendin‑4 increased bone strength.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBone strength
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Exendin-4 also enhanced bone strength and prevented the deterioration of trabecular microarchitecture.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705604
05AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 prevented deterioration of trabecular microarchitecture.
In plain wordsIn rats with ovaries removed, exendin‑4 prevented deterioration of internal bone structure.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTrabecular microarchitecture deterioration
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Exendin-4 also enhanced bone strength and prevented the deterioration of trabecular microarchitecture.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705605
06AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 decreased the urinary DPD/creatinine ratio.
In plain wordsIn rats with ovaries removed, exendin‑4 reduced a urine marker of bone breakdown.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUrinary DPD/creatinine ratio
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, exendin-4 decreased the urinary deoxypyridinoline (DPD)/creatinine ratio and serum C-terminal cross-linked telopeptides of type I collagen (CTX-I) and increased serum alkaline phosphatase (ALP), osteocalcin (OC), and N-terminal propeptide of type 1 procollagen (P1NP) levels, key biochemica…
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705606
07AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 decreased serum CTX-I.
In plain wordsIn rats with ovaries removed, exendin‑4 reduced blood CTX-I.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerum CTX-I
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, exendin-4 decreased the urinary deoxypyridinoline (DPD)/creatinine ratio and serum C-terminal cross-linked telopeptides of type I collagen (CTX-I) and increased serum alkaline phosphatase (ALP), osteocalcin (OC), and N-terminal propeptide of type 1 procollagen (P1NP) levels, key biochemica…
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705607
08AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 increased serum ALP.
In plain wordsIn rats with ovaries removed, exendin‑4 increased blood ALP.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum ALP
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, exendin-4 decreased the urinary deoxypyridinoline (DPD)/creatinine ratio and serum C-terminal cross-linked telopeptides of type I collagen (CTX-I) and increased serum alkaline phosphatase (ALP), osteocalcin (OC), and N-terminal propeptide of type 1 procollagen (P1NP) levels, key biochemica…
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705608
09AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 increased serum osteocalcin.
In plain wordsIn rats with ovaries removed, exendin‑4 increased blood osteocalcin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum osteocalcin
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, exendin-4 decreased the urinary deoxypyridinoline (DPD)/creatinine ratio and serum C-terminal cross-linked telopeptides of type I collagen (CTX-I) and increased serum alkaline phosphatase (ALP), osteocalcin (OC), and N-terminal propeptide of type 1 procollagen (P1NP) levels, key biochemica…
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705609
10AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 increased serum P1NP.
In plain wordsIn rats with ovaries removed, exendin‑4 increased blood P1NP.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum P1NP
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, exendin-4 decreased the urinary deoxypyridinoline (DPD)/creatinine ratio and serum C-terminal cross-linked telopeptides of type I collagen (CTX-I) and increased serum alkaline phosphatase (ALP), osteocalcin (OC), and N-terminal propeptide of type 1 procollagen (P1NP) levels, key biochemica…
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705610
11AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 inhibited bone resorption.
In plain wordsIn rats with ovaries removed, exendin‑4 inhibited bone breakdown.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBone resorption
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Interestingly, gene expression results further showed that exendin-4 not only inhibited bone resorption by increasing the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705611
12AnimalAnimal study (in vivo)Mechanism
In old ovariectomized rats, exendin‑4 increased the OPG/RANKL ratio.
In plain wordsIn rats with ovaries removed, exendin‑4 increased the OPG/RANKL ratio.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOPG/RANKL ratio
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
Interestingly, gene expression results further showed that exendin-4 not only inhibited bone resorption by increasing the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) ratio,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705612
13AnimalAnimal study (in vivo)Efficacy outcome
In old ovariectomized rats, exendin‑4 promoted bone formation.
In plain wordsIn rats with ovaries removed, exendin‑4 promoted bone formation.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBone formation
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
but also promoted bone formation by increasing the expression of OC, Col1, Runx2, and ALP,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705613
14AnimalAnimal study (in vivo)Mechanism
In old ovariectomized rats, exendin‑4 increased OC gene expression.
In plain wordsIn rats with ovaries removed, exendin‑4 increased OC gene expression.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOC gene expression
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
but also promoted bone formation by increasing the expression of OC, Col1, Runx2, and ALP,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705614
15AnimalAnimal study (in vivo)Mechanism
In old ovariectomized rats, exendin‑4 increased Col1 gene expression.
In plain wordsIn rats with ovaries removed, exendin‑4 increased Col1 gene expression.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCol1 gene expression
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
but also promoted bone formation by increasing the expression of OC, Col1, Runx2, and ALP,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705615
16AnimalAnimal study (in vivo)Mechanism
In old ovariectomized rats, exendin‑4 increased Runx2 gene expression.
In plain wordsIn rats with ovaries removed, exendin‑4 increased Runx2 gene expression.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRunx2 gene expression
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
but also promoted bone formation by increasing the expression of OC, Col1, Runx2, and ALP,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705616
17AnimalAnimal study (in vivo)Mechanism
In old ovariectomized rats, exendin‑4 increased ALP gene expression.
In plain wordsIn rats with ovaries removed, exendin‑4 increased ALP gene expression.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseALP gene expression
Study
ratn: not reported in source
Aged ovariectomized female Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 16 weeksAs given in this study (rat).
Source sentences
Summary
but also promoted bone formation by increasing the expression of OC, Col1, Runx2, and ALP,
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old female Sprague-Dawley rats were subjected to OVX, and exendin-4 was administrated 4 weeks after the surgery and lasted for 16 weeks.
Report a problemFND-2342705617

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.